CMP
NVO

Coston McIsaac & Partners’s Novo Nordisk NVO Stock Holding History

Coston McIsaac & Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Hold
40
– – ﹤0.01% 811
2026
Q1 		$1K Hold
40
– – ﹤0.01% 796
2025
Q4 		$2K Buy
+40
New +$2.04K ﹤0.01% 749

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Coston McIsaac & Partners's NVO Position: Q2 2026 in Review

Coston McIsaac & Partners held its Novo Nordisk (NVO) position steady in Q2 2026 at 40 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #811.

Coston McIsaac & Partners first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $2K in Q4 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Coston McIsaac & Partners held 40 shares of Novo Nordisk worth $1K as of Q2 2026.
  • Coston McIsaac & Partners left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #811 holding.
  • Coston McIsaac & Partners first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Coston McIsaac & Partners's Novo Nordisk position peaked at $2K in Q4 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.